BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals) 

Alexandria Center for Life Sciences
450 East 29th Street, 5th Floor
New York  New York  10016  U.S.A.
Phone: 212-308-6000 Fax: n/a


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Kadmon Corporation Announces The Initiation Of KD025 Phase 2 Program In Psoriasis 4/8/2014 10:32:36 AM    More...
Kadmon Corporation Presents Preclinical Results Demonstrating KD019 Activity In Trastuzumab Resistant HER2+ Breast Cancer 4/8/2014 10:26:44 AM    More...
Kadmon Corporation Presents Results At The 9th International Congress On Autoimmunity Demonstrating The Effects Of KD025 On Immune Homeostasis 3/28/2014 8:23:27 AM    More...
Kadmon Pharmaceuticals Announces Co-Promotion Agreement With Valeant Pharmaceuticals North America And For SYPRINE® (Trientine Hydrochloride) In Wilson's Disease 2/25/2014 10:28:07 AM    More...
Kadmon Pharmaceuticals To Present At The RBC Capital Markets 2014 Global Healthcare Conference 2/19/2014 10:55:17 AM    More...
Kadmon Pharmaceuticals Doses First Patient in Phase 1b/2a Study of KD020 in Polycystic Kidney Disease 10/24/2012 8:44:14 AM    More...
Dyax Corp. (DYAX) and Kadmon Pharmaceuticals Sign Strategic Licensing Agreement for DX-2400 9/20/2012 9:27:13 AM    More...
Kadmon Pharmaceuticals Launches 600 mg/day Ribasphere(R) RibaPak(R) to Provide Added Dosing Control for Triple Therapy Treatment of Chronic Hepatitis C 6/5/2012 9:13:01 AM    More...
Biodesix, Inc. Announces Phase 3 Clinical Trial Collaboration with Kadmon Pharmaceuticals 2/27/2012 6:30:18 AM    More...
Kadmon Pharmaceuticals Release: Pill Burden a Key Concern With New Chronic Hepatitis C Drugs 5/19/2011 8:48:48 AM    More...